Jounce Therapeutics (NASDAQ:JNCE) and Allena Pharmaceuticals (NASDAQ:ALNA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.
Institutional & Insider Ownership
73.3% of Jounce Therapeutics shares are held by institutional investors. Comparatively, 79.7% of Allena Pharmaceuticals shares are held by institutional investors. 44.0% of Jounce Therapeutics shares are held by company insiders. Comparatively, 38.6% of Allena Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This is a breakdown of current ratings and price targets for Jounce Therapeutics and Allena Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Jounce Therapeutics presently has a consensus target price of $11.67, indicating a potential upside of 182.49%. Allena Pharmaceuticals has a consensus target price of $24.60, indicating a potential upside of 443.05%. Given Allena Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Allena Pharmaceuticals is more favorable than Jounce Therapeutics.
Valuation and Earnings
This table compares Jounce Therapeutics and Allena Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Jounce Therapeutics||$65.20 million||2.09||-$27.38 million||($0.84)||-4.92|
|Allena Pharmaceuticals||N/A||N/A||-$35.65 million||($1.72)||-2.63|
Jounce Therapeutics has higher revenue and earnings than Allena Pharmaceuticals. Jounce Therapeutics is trading at a lower price-to-earnings ratio than Allena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Jounce Therapeutics has a beta of 3.45, suggesting that its share price is 245% more volatile than the S&P 500. Comparatively, Allena Pharmaceuticals has a beta of 1.98, suggesting that its share price is 98% more volatile than the S&P 500.
This table compares Jounce Therapeutics and Allena Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Jounce Therapeutics beats Allena Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
Jounce Therapeutics Company Profile
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform. It is also developing JTX-4014, a monoclonal antibody that is in Phase I clinical trial for combination therapy; and JTX-8064, a monoclonal antibody that binds to leukocyte immunoglobulin like receptor B2 that is in the IND-enabling phase. The company has a master research and collaboration agreement with Celgene Corporation focused on developing and commercializing biologic immunotherapies. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
Allena Pharmaceuticals Company Profile
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was founded in 2011 and is headquartered in Newton, Massachusetts.
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.